{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:24:59Z","timestamp":1774538699670,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1124\/dmd.116.073940","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T01:40:47Z","timestamp":1489196447000},"page":"676-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Metabolite Identification, Reaction Phenotyping, and Retrospective Drug-Drug Interaction Predictions of 17-Deacetylnorgestimate, the Active Component of the Oral Contraceptive Norgestimate"],"prefix":"10.1016","volume":"45","author":[{"given":"Deepak","family":"Ahire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarmistha","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramaswamy","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Mandlekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.116.073940_bib1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dki308","article-title":"Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals","volume":"56","author":"Almond","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.116.073940_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0010-7824(84)90055-6","article-title":"Biotransformation of norgestimate in women","volume":"29","author":"Alton","year":"1984","journal-title":"Contraception"},{"key":"10.1124\/dmd.116.073940_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2125.2010.03885.x","article-title":"Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women","volume":"71","author":"Anderson","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.116.073940_bib4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1468-1293.2009.00767.x","article-title":"Lopinavir protein binding in HIV-1-infected pregnant women","volume":"11","author":"Aweeka","year":"2010","journal-title":"HIV Med"},{"key":"10.1124\/dmd.116.073940_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/00016349009156504","article-title":"Supportive European data on a new oral contraceptive containing norgestimate","volume":"152","author":"Becker","year":"1990","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"10.1124\/dmd.116.073940_bib6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3851\/IMP2718","article-title":"Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate","volume":"19","author":"Bifano","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.116.073940_bib7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0002-9378(92)91397-S","article-title":"Norgestimate: a clinical overview of a new progestin","volume":"166","author":"Bringer","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.116.073940_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/135965350601100112","article-title":"Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures","volume":"11","author":"Colombo","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.116.073940_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/00016349009156503","article-title":"Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials","volume":"152","author":"Corson","year":"1990","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"10.1124\/dmd.116.073940_bib10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jcph.298","article-title":"Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations","volume":"54","author":"Delille","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.116.073940_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of CYP3A by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.116.073940_bib12","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.073940_bib13","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/jcph.346","article-title":"Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate\/ethinyl estradiol in HCV-uninfected female subjects","volume":"54","author":"German","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.116.073940_bib14","unstructured":"German P, Wang M, Warren D, and Kearney B (2011). Pharmacokinetic interaction between norgestima\/ethinyl estradiol and EVG\/COBI\/FTC\/TDF single tablet regimen, in Proccedings of 12th International Workshop on Clinical Pharmacology of HIV Therapy; 2011 April 13\u201315, Miami, FL."},{"key":"10.1124\/dmd.116.073940_bib15","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/0091270004269142","article-title":"Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital","volume":"44","author":"Hariparsad","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/dmd.116.073940_bib16","first-page":"25","article-title":"Clinical experience with a new norgestimate-containing oral contraceptive","volume":"36","author":"Huber","year":"1991","journal-title":"Int J Fertil"},{"key":"10.1124\/dmd.116.073940_bib17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2125.2008.03198.x","article-title":"Maraviroc: in vitro assessment of drug-drug interaction potential","volume":"66","author":"Hyland","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.116.073940_bib18","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0002-9378(12)90411-1","article-title":"A norgestimate-containing oral contraceptive: review of clinical studies","volume":"167","author":"Kafrissen","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.116.073940_bib19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/dmd.106.012294","article-title":"Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios","volume":"35","author":"Kalvass","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.073940_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/106002809502907-817","article-title":"Desogestrel, norgestimate, and gestodene: the newer progestins","volume":"29","author":"Kaplan","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.116.073940_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1592\/phco.29.8.924","article-title":"Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives","volume":"29","author":"Kearney","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.116.073940_bib22","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1128\/AAC.01600-07","article-title":"Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir","volume":"52","author":"Kharasch","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.116.073940_bib23","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1124\/dmd.111.038646","article-title":"Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.073940_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/bdd.1788","article-title":"Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS\/MS cocktail assays and RT-PCR","volume":"33","author":"Liu","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.116.073940_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0960-0760(91)90338-6","article-title":"Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro","volume":"38","author":"Madden","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.116.073940_bib26","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/0002-9378(90)90552-I","article-title":"Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites","volume":"163","author":"McGuire","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.116.073940_bib27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/pharmaceutics3040745","article-title":"Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management","volume":"3","author":"Rathbun","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1124\/dmd.116.073940_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0091270004272732","article-title":"Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women","volume":"45","author":"Roy","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/dmd.116.073940_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2230.2011.04031.x","article-title":"Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol\/norgestimate","volume":"36","author":"Schmitt-Hoffmann","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1124\/dmd.116.073940_bib30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MJT.0b013e3181985130","article-title":"Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women","volume":"16","author":"Schwartz","year":"2009","journal-title":"Am J Ther"},{"key":"10.1124\/dmd.116.073940_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3851\/IMP1725","article-title":"The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women","volume":"16","author":"Sevinsky","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.116.073940_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/2193-9616-1-4","article-title":"Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz","volume":"1","author":"Siccardi","year":"2013","journal-title":"In Silico Pharmacol"},{"key":"10.1124\/dmd.116.073940_bib33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2125.2003.02015.x","article-title":"The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive","volume":"57","author":"Simonson","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.116.073940_bib34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/1060028015580637","article-title":"Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol","volume":"49","author":"Song","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.116.073940_bib35","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1463-1326.2012.01635.x","article-title":"Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen\u00ae, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women","volume":"14","author":"Upreti","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/dmd.116.073940_bib36","unstructured":"U.S. Department of Health and Human Services (2012) Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations."},{"key":"10.1124\/dmd.116.073940_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0b013e3181eb5ff5","article-title":"Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188","volume":"55","author":"Vogler","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.116.073940_bib38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1211\/002235702739","article-title":"Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir","volume":"55","author":"Weemhoff","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.116.073940_bib39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0960-0760(91)90248-4","article-title":"Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture","volume":"39","author":"Wild","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.116.073940_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0960-0760(93)90010-T","article-title":"Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro","volume":"45","author":"Wild","year":"1993","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.116.073940_bib41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2133\/dmpk.DMPK-12-RG-124","article-title":"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19","volume":"28","author":"Xu","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.116.073940_bib42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.115.067876","article-title":"Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method","volume":"44","author":"Yang","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.073940_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.116.073940_bib44","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.073940_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP1724","article-title":"The effect of atazanavir\/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women","volume":"16","author":"Zhang","year":"2011","journal-title":"Antivir Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624053297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624053297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.116.073940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:21:29Z","timestamp":1739902889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624053297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0090955624053297"],"URL":"https:\/\/doi.org\/10.1124\/dmd.116.073940","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolite Identification, Reaction Phenotyping, and Retrospective Drug-Drug Interaction Predictions of 17-Deacetylnorgestimate, the Active Component of the Oral Contraceptive Norgestimate","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.116.073940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}